Prescription opioid use, harms and interventions in canada: A review update of new developments and findings since 2010

Pain Physician

Volumn 18, Issue 4, 2015, Pages E605-E614

  Murphy, Yoko ^a,c   Goldner, Elliot M ^b,c   Fischer, Benedikt ^a,c,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canada; Dispensing; Dosing; Education; Interventions; Monitoring; Morbidity; Mortality; Non medical use; Policy; Prescription opioids; Review; Use

Indexed keywords

FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANADA; COLORECTAL CANCER; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; METHADONE TREATMENT; MORBIDITY; MORTALITY; PALLIATIVE THERAPY; PHARMACY; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; WITHDRAWAL SYNDROME; DRUG UTILIZATION; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA;

ANALGESICS, OPIOID; CANADA; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; OPIOID-RELATED DISORDERS;

EID: 84938117758     PISSN: 15333159     EISSN: 21501149     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician 2012; 15:ES191-ES203.
2. Fischer B, Keates A, Buhringer G, Reimer J, Rehm J. Non-medical use of prescription opioids and prescription opioid-related harms: Why so markedly higher in North America compared to the rest of the world? Addiction 2014; 109:177-181.
3. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011; 305:1346-1347.
4. Manchikanti L, Atluri S, Hansen H, Be-nyamin RM, Falco FJ, Helm li S, Kaye AD, Hirsch JA. Opioids in chronic non-cancer pain: Have we reached a boiling point yet? Pain Physician 2014; 17:1-10.
5. Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician 2014; 17:E119-E128.
6. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372:241-248.
7. lnternational Narcotics Control Board (INCB). Narcotic Drugs Estimated World Requirements for 2014 - Statistics for 2012. 2014; T.14.XI.2.
8. Morgan S, Smolina K, Mooney D, Raymond C, Bowen M, Gorczynski C, Rutherford K. The Canadian Rx Atlas. 3rd edition. Centre for Health Services and Policy Research, Vancouver, 2013.
9. Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: An update with a focus on recent interventions. BMC Health Serv Res 2014; 14:90.
10. Gomes T, Mamdani MM, Paterson JM, Dhalla IA, Juurlink DN. Trends in highdose opioid prescribing in Canada. Can Fam Physician 2014; 60:826-832
11. Health Canada. Canadian Alcohol and Drug Use Monitoring Survey (CADU-MS): Summary of Results for 2012. 2014; Available at: www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.php. Accessed May 1, 2014.
12. Lalomiteanu A, Hamilton H, Adlaf E, Mann R. CAMH Monitor ereport: Substance use, mental health and well-being among Ontario adults, 1977-2013. 2014; CAMH Research Document Series No. 40.
13. Patented Medicine Prices Review Board (PMPRB). Utilization of Prescription Opioids in Canada's Public Drug Plans, 2006/07 to 2012/13. 2014.
14. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011; 5:e13-e22.
15. Allen MJ, Asbridge MM, Macdougall PC, Furlan AD, Tugalev O. Self-reported practices in opioid management of chronic noncancer pain: A survey of Canadian family physicians. Pain Res Manag 2013; 18:177-184.
16. Clarke H, Soneji N, Ko DT, Yun L, Wi-jeysundera DN. Rates and risk factors for prolonged opioid use after major surgery: Population based cohort study. BMJ 2014; 348:g1251.
17. Kraut A, Shafer LA, Raymond CB. Proportion of opioid use due to compensated workers' compensation claims in Manitoba, Canada. American Journal of Industrial Medicine 2015; 58:33-39.
18. Gagnon B, Scott S, Nadeau L, Lawlor PG. Patterns of community-based opioid prescriptions in people dying of cancer. J Pain Symptom Manage 2015; 49:36-44.
19. Kurdyak P, Gomes T, Yao Z, Mamdani MM, Hellings C, Fischer B, Rehm J, Bayoumi AM, Juurlink DN. Use of other opioids during methadone therapy: A population-based study. Addiction 2012; 107:776-780.
20. Nosyk B, Fischer B, Sun H, Marsh D, Kerr T, Rehm J, Anis A. High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. Am J Addict 2014; 23:257-264.
21. Voon P, Callon C, Nguyen P, Dobrer S, Montaner JS, Wood E, Kerr T. Denial of prescription analgesia among people who inject drugs in a Canadian setting. Drug Alcohol Rev 2015; 34:221-228.
22. Health Canada. Canadian Alcohol and Drug Use Monitoring Survey (CADU-MS): Summary of Results for 2011. 2012; Available at: www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2011/summary-sommaire-eng.php. Accessed November 23, 2012.
23. Fischer B, Ialomiteanu A, Boak A, Adlaf E, Rehm J, Mann R. Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. Drug Alcohol Rev 2013; 32:276-287.
24. Currie CL, Schopflocher DP, Wild TC. Prevalence and correlates of 12-month prescription drug misuse in Alberta. Can J Psychiatry 2011; 56:27-34.
25. Health Canada. Summary of Results of the 2012-13 Youth Smoking Survey. 2014; Available at: www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_survey-sondage_2012-2013/result-eng.php. Accessed 01/07, 2015.
26. Boak A, Hamilton HA, Adlaf EM, Mann RE. Drug Use among Ontario Students, 1977-2013: Detailed OSDUHS Findings (CAMH Research Document Series No. 36). 2013.
27. Smith A, Stewart D, Poon C, Peled M, Saewyc E; McCreary Centre Society. From Hastings Street to Haida Gwaii: Provincial results of the 2013 BC Adolescent Health Survey. McCreary Centre Society, Vancouver, 2014.
28. Asbridge M, Langille D. Nova Scotia Student Drug Use Survey 2012: Technical Report. Dalhousie University, Halifax, 2013.
29. Department of Health and Community Services. Newfoundland and Labrador 2012 Student Drug Use Survey: Highlights Report. Department of Health and Community Services, St. John's, 2013.
30. Gupta N, Wang H, Collette M, Pilgrim W. New Brunswick Student Drug Use Survey Report 2012. Department of Health, Fredericton, 2013.
31. Cheverie C, Henry S, MacSwain M, McClure C, Sanford C. Prince Edward Island Student Drug Use 2004-2011. Prince Edward Island Department of Health and Wellness, Charlottetown, 2013.
32. Public Health Agency of Canada. I-Track: Enhanced Surveillance of Risk Behaviours among People who Inject Drugs -Phase I Report. Public Health Agency of Canada, Ottawa, 2006.
33. Public Health Agency of Canada. I-Track: Enhanced Surveillance of HIV, Hepatitis C and associated risk behaviours among people who inject drugs in Canada. Phase 2 Report. Public Health Agency of Canada, Ottawa 2014.
34. Argento E, Chettiara J, Nguyena P, Montanera J, Shannon K. Prevalence and correlates of nonmedical prescription opioid use among a cohort of sex workers in Vancouver, Canada. Int J Drug Policy 2015; 26:59-66.
35. Kouyoumdjian FG, Calzavara LM, Kiefer L, Main C, Bondy SJ. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada. Can J Public Health 2014; 105:e198-e202.
36. The First Nations Information Governance Centre. First Nations Regional Health Survey (RHS) Phase 2 (2008/10) National Report on Adults, Youth and Children Living in First Nations Communities. The First Nations Information Governance Centre, Ottawa, 2012.
37. Katt M, Chase C, Samokhvalov AV, Argento E, Rehm J, Fischer B. Feasibility and outcomes of a community-based taper-to-low-dose-maintenance subox-one treatment program for prescription opioid dependence in a remote First Nations community in northern Ontario. J Aborig Health 2012; 9:52.
38. Currie CL, Wild TC. Adolescent use of prescription drugs to get high in Canada. Can J Psychiatry 2012; 57:745-751.
39. Drug and Alcohol Treatment Information System (DATIS). Substance Abuse Statistical Tables: Fiscal Year 2007/2008 to Fiscal Year 2012/2013. 2013.
40. Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmaco-epidemiol Drug Saf 2013; 22:438-442.
41. Hadland SE, DeBeck K, Kerr T, Feng C, Montaner JS, Wood E. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open 2014; 4:e005419
42. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012; 107:1318.
43. Turner S, Gomes T, Camacho X, Yao Z, Guttmann A, Mamdani MM, Juurlink DN, Dhalla IA. Neonatal opioid withdrawal and antenatal opioid prescribing. CMAJ 2015; 3:E55-E61.
44. Kelly L, Guilfoyle J, Dooley J, Antone I, Gerber-Finn L, Dooley R, Brunton N, Kakegamuck K, Muileboom J, Hopman W, Cromarty H, Linkewich B, Maki J. Incidence of narcotic abuse during pregnancy in northwestern Ontario: Three-year prospective cohort study. Can Fam Physician 2014; 60:493-498.
45. Kelly L, Dooley J, Cromarty H, Minty B, Morgan A, Madden S, Hopman W. Narcotic-exposed neonates in a First Nations population in northwestern Ontario: Incidence and implications. Can Fam Physician 2011; 57:e441-e447.
46. Asbridge M, Cartwright J, Langille D. Driving under the influence of opioids among high school students in Atlantic Canada: Prevalence, correlates, and the role of medical versus recreational consumption. Accid Anal Prev 2014; 75C:184-191.
47. Gomes T, Redelmeier DA, Juurlink DN, Dhalla IA, Camacho X, Mamdani MM. Opioid dose and risk of road trauma in Canada: A population-based study. JAMA Internal Medicine 2013; 173:196-201.
48. Office of the Chief Coroner (Ontario). Office of the Chief Coroner Report for 2009-2011. 2012.
49. Office of the Chief Coroner (Ontario). Number of Opioid Related Deaths by Drug 2002-2013. 2014.
50. Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The burden of premature opioid-related mortality. Addiction 2014; 109:1482-1488.
51. Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: A population-based study in Ontario, Canada. PLoS One 2013; 8:e60600.
52. Fischer B, Jones W, Urbanoski K, Skinner R, Rehm J. Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011. Drug Alcohol Rev 2013; 33:19-26.
53. Gomes T, Juurlink DN, Moineddin R, Gozdyra P, Dhalla I, Paterson M, Mam-dani MM. Geographical variation in opioid prescribing and opioid-related mortality in Ontario. Healthc Q 2011; 14:22-24.
54. BC Coroners Service. Prescription opiate-related overdose deaths 2005-2010. 2013.
55. BC Coroners Service. Fentanyl-detected deaths in illicit drug circumstances 2012 -2014(YTD). 2014.
56. BC Coroners Service. Illicit drug overdose deaths in BC 2009-2013. 2014.
57. Gagné M, Dube PA, Perron PA, Langlois E, Legare G, Sirois MJ, Aubut C, Lefe-bvre M, St Laurent M. Opioid-related poisoning deaths in Québec: 2000 to 2009. Institut National de Santé Publique du Québec, Québec, 2013.
58. Fisher J, Urquhart R, Johnston G. Use of opioid analgesics among older persons with colorectal cancer in two health districts with palliative care programs. J Pain Symptom Manage 2013; 46:20-29.0
59. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A; National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 2: Special populations. Can Fam Physician 2011; 57:1269-1276.
60. Furlan AD, Reardon R, Weppler C, for the National Opioid Use Guideline Group (NOUGG). Opioids for chronic noncancer pain: A new Canadian practice guideline. CMAJ 2010; 182:923-930.
61. Weeks C. OxyContin delisting not the answer to opioid addiction, experts say. The Globe and Mail. February 26, 2012.
62. Fischer B, Keates A. 'Opioid drought', Canadian-style? Potential implications of the 'natural experiment' of delisting Oxycontin in Canada. Int J Drug Policy 2012; 23:495-497.
63. Furlan AD, MacDougall P, Pellerin D, Shaw K, Spitzig D, Wilson G, Wright J. Overview of four prescription monitoring/review programs in Canada. Pain Research & Management 2014; 19:102-106.
64. Ministry of Health and Long Term Care. Ontario's Narcotics Monitoring System. 2012; Available at: http://news.ontario.ca/mohltc/en/2012/05/ontarios-narcot-ics-monitoring-system.html. Accessed 02/07, 2015.
65. National Advisory Committee on Prescription Drug Misuse. First Do No Harm: Responding to Canada's Prescription Drug Crisis. Canadian Centre on Substance Abuse, Ottawa, 2013.
66. Expert Working Group on Narcotic Addiction. The Way Forward: Stewardship for Prescription Narcotics in Ontario. Ontario Ministry of Health and Long-Term Care, Concord, 2012.
67. Health Canada. Consultation on the Draft Guidance Document: Tamper-Resistant Formulations of Opioid Drug Product Submissions. 2014; Available at: www.hc-sc.gc.ca/dhp-mps/consulta-tion/drug-medic/consult_draft_guid_opioid_ebauche_ld-eng.php. Accessed 02/07, 2015.
68. CBC News. Opioid painkillers to get stronger warning labels, Health Minister says. CBC News 2014.
69. King S. OxyContin in Ontario: The multiple materialities of prescription painkillers. Int J Drug Policy 2014; 25:486-493.
70. Borwein A, Kephart G, Whelan E, Asbridge M. Prescribing practices amid the oxycontin crisis: Examining the effect of print media coverage on opioid prescribing among physicians. J Pain 2013; 14:1686-1693.
71. Fischer B, Jones W, Murphy Y, Ialomite-anu A, Rehm J. Recent Developments in Prescription Opioid-related Dispensing and Harm Indicators in Ontario, Canada. Pain Physician in press.
72. Ministry of Health and Long-Term Care. A Review of the Impacts of Opiate Use in Ontario: Interim Summary Report. 2013.
73. Ministry of Health and Long-Term Care. A Review of the Impacts of Opiate Use in Ontario: Summary Report. 2013.
74. Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN. Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMA J 2012; 184:E852-E856.
75. Gomes T, Juurlink D, Yao Z, Camacho X, Paterson JM, Singh S, Dhalla I, Sproule B, Mamdani M. Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: A time series analysis. CMAJ Open 2014; 2:256-261.
76. Fisher JE, Zhang Y, Sketris I, Johnston G, Burge F. The effect of an educational intervention on meperidine use in Nova Scotia, Canada: A time series analysis. Pharmacoepidemiol Drug Saf 2012; 21:177-183.
77. Kahan M, Gomes T, Juurlink DN, Manno M, Wilson L, Mailis-Gagnon A, Srivas-tava A, Reardon R, Dhalla IA, Mamdani MM. Effect of a course-based intervention and effect of medical regulation on physicians' opioid prescribing. Canadian Family Physician 2013; 59:231-239.
78. Srivastava A, Kahan M, Jiwa A. Prescription opioid use and misuse piloting an educational strategy for rural primary care physicians. Canadian Family Physician 2012; 58:e210-e216.
79. Gomes T, Paterson JM, Juurlink DN, Dhalla IA, Mamdani MM. Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US-Canada border. Open Med 2012; 6:141-145.
80. Handford C, Kahan M, Srivastava A, Cirone S, Palda V. Buprenorphine/Nal-oxone for Opioid Dependence: Clinical Practice Guideline. Centre for Addiction and Mental Health, Toronto, 2011.
81. Kanate D, Folk D, Cirone S, Gordon J, Kirlew M, Veale T, Bocking N, Rea S, Kelly L. Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: Evaluating outpatient buprenor-phine-naloxone substitution therapy in the context of a First Nations healing program. Can Fam Physician 2015; 61:160-165.
82. Dooley R, Dooley J, Antone I, Guilfoyle J, Gerber-Finn L, Kakekagumick K, Cromarty H, Hopman W, Muileboom J, Brunton N, Kelly L. Narcotic tapering in pregnancy using long-acting morphine: An 18-month prospective cohort study in northwestern Ontario. Can Fam Physician 2015; 61:E88-E95.
83. Fischer B, Gooch J, Goldman B, Kurdyak P, Rehm J. Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: A update 5 years later. Can J Public Health 2014; 105:146-149.